Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Palumbo

Showing results (361-370 of 497) with videos related to

Pageof 50
Sort By:
Journal of Clinical Medicine|March 25, 2022
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic SyndromesCalogero Vetro, Valeria Di Giacomo, Donato Mannina, et al.
Leukemia|March 4, 2005
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myelomaS Mariani, M Muraro, F Pantaleoni, et al.
La Radiologia Medica|October 24, 2007
Diagnostic accuracy of 64-slice computed tomography coronary angiography in patients with low-to-intermediate riskF Cademartiri, E Maffei, A Palumbo, et al.
British Journal of Haematology|July 10, 2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinibElena Crisà, Daniela Cilloni, Elena M Elli, et al.
La Radiologia Medica|October 31, 2008
Noninvasive evaluation of the celiac trunk and superior mesenteric artery with multislice CT in patients with chronic mesenteric ischaemiaF Cademartiri, A Palumbo, E Maffei, et al.
Journal of Chemotherapy (Florence, Italy)|June 28, 2007
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphismsS Galimberti, G A Palumbo, F Caracciolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2008
Bortezomib, doxorubicin and dexamethasone in advanced multiple myelomaA Palumbo, F Gay, S Bringhen, et al.
Leukemia|October 31, 2003
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))A Palumbo, S Bringhen, A Bertola, et al.
Oncogenesis|October 13, 2021
Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcomaDarko Bosnakovski, Elizabeth T Ener, Mark S Cooper, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
Pageof 50

Showing results (361-370 of 497) with videos related to

Sort By:
Pageof 50
Journal of Clinical Medicine|March 25, 2022
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic SyndromesCalogero Vetro, Valeria Di Giacomo, Donato Mannina, et al.
Leukemia|March 4, 2005
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myelomaS Mariani, M Muraro, F Pantaleoni, et al.
La Radiologia Medica|October 24, 2007
Diagnostic accuracy of 64-slice computed tomography coronary angiography in patients with low-to-intermediate riskF Cademartiri, E Maffei, A Palumbo, et al.
British Journal of Haematology|July 10, 2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinibElena Crisà, Daniela Cilloni, Elena M Elli, et al.
La Radiologia Medica|October 31, 2008
Noninvasive evaluation of the celiac trunk and superior mesenteric artery with multislice CT in patients with chronic mesenteric ischaemiaF Cademartiri, A Palumbo, E Maffei, et al.
Journal of Chemotherapy (Florence, Italy)|June 28, 2007
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphismsS Galimberti, G A Palumbo, F Caracciolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2008
Bortezomib, doxorubicin and dexamethasone in advanced multiple myelomaA Palumbo, F Gay, S Bringhen, et al.
Leukemia|October 31, 2003
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))A Palumbo, S Bringhen, A Bertola, et al.
Oncogenesis|October 13, 2021
Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcomaDarko Bosnakovski, Elizabeth T Ener, Mark S Cooper, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
Pageof 50